The mondriaan project: The dutch healthcare landscape as a population laboratory

Olaf H. Klungel, Marc C. Rietveld, Mark C.H. De Groot, Ronald P. Stolk, Maarten J. Postma, Hubert G.M. Leufkens, Toine C.G. Egberts, Anke M. Hovels, Lex Van De Langerijt, Willem De Bruijn, Arno W. Hoes, Diederik E. Grobbe



    Background: The gap between pre-clinical pharmaceutical research and clinical/epidemiological research hampers optimal benefit-risk assessment and monitoring of new and existing medicines. Many excellent health care databases are available in the Netherlands for pharmaco-epidemiologic and -economic research. However, in isolation these data remain scattered and have limitations with regard to sample sizes and/or detail of the registered information. Objectives: To optimize routine health care databases in the Netherlands for pharmaco-epidemiologic and economic research in order to improve benefit-risk assessment and monitoring of new and existing medicines. Methods: We build an ICT infrastructure for linkage of healthcare/research databases in the Netherlands. To protect privacy, pseudonimisation and linkage was performed by a trusted third party (TTP). A data catalogue was developed to allow queries over the integrated databases which will help in designing pharmacoepidemiologic studies (incl. sample size calculations, assessment of completeness of data). Results: We linked pharmacy records from the National Foundation of Pharmaceutical Statistics (n>12,000,000) on a patient base to several routine health care databases such as the Almere Health Care database (n=160,000), the Utrecht Health Project (n=20,000), and the AGIS claims database (n=1,200,000). Currently we are integrating several other databases in the Netherlands. Conclusions: The project will deliver a large-scale, highquality data platform for innovative pharmaceutical research and provide the tools to improve benefit-risk assessment of medicines.
    Originele taal-2English
    Pagina's (van-tot)177-178
    Aantal pagina's2
    TijdschriftPharmacoepidemiology and Drug Safety
    StatusPublished - 1-aug-2010

    Citeer dit